Literature DB >> 17206455

Improvements of hypertriglyceridemia and hyperlacticemia in Japanese children with glycogen storage disease type Ia by medium-chain triglyceride milk.

Hironori Nagasaka1, Ken-ichi Hirano, Akira Ohtake, Takashi Miida, Tomozumi Takatani, Kei Murayama, Tohru Yorifuji, Kunihiko Kobayashi, Masaki Kanazawa, Atsushi Ogawa, Masaki Takayanagi.   

Abstract

BACKGROUND: Besides profound hypoglycemia with hyperlacticemia, glycogen storage disease type Ia (GSD Ia) presents hypertriglyceridemia that is often resistant to dietary treatment with cornstarch. The present study aimed to evaluate the effects of medium-chain triglycerides (MCT)--which are absorbed via the portal vein without being incorporated into chylomicrons--on hypertriglyceridemia and to explore otherwise metabolic changes in children with GSD Ia. PATIENTS AND METHODS: A 13-year-old boy with GSD Ia who received a dietary treatment with MCT milk after cornstarch administration and two infants also with GSD Ia, ages 6 and 7 months, who received MCT milk after carbohydrate-rich, lipid-poor milk were enrolled. In addition to serum glucose and lactate levels, serum levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol were serially determined. Simultaneously, serum levels of total carnitine, free carnitine, acylcarnitine, and ketone bodies were determined to evaluate fatty acid beta-oxidation.
RESULTS: Mean glucose level (mmol/l) of patient 1 remained stable, the value being around 4.5, while those of patients 2 and 3 increased to this level from 4.00 and 3.72, respectively. Lactate levels were significantly decreased in all patients. Mean triglyceride levels (mM) of patient 1 decreased from 3.00 to 2.05. Also, triglyceride levels of patients 2 and 3 decreased from 2.74 and 3.15 to 2.13 and 2.70, respectively. HDL cholesterol, acylcarnitine, and ketone body levels increased in all patients after MCT administration, while total and free carnitine levels decreased.
CONCLUSION: We describe here the beneficial effects on lipid and carbohydrate metabolisms in three Japanese children with GSD Ia. In light of the unfavorable influence of lipid restriction on growth and development in infancy, dietary treatment with MCT milk may be a better treatment for infants with GSD Ia. Further investigation should be required to confirm the efficacy of MCT milk in GSD Ia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206455     DOI: 10.1007/s00431-006-0372-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

2.  Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells.

Authors:  J Akanuma; T Nishigaki; K Fujii; Y Matsubara; K Inui; K Takahashi; S Kure; Y Suzuki; T Ohura; S Miyabayashi; E Ogawa; K Iinuma; S Okada; K Narisawa
Journal:  Am J Med Genet       Date:  2000-03-13

3.  Modifications in electrospray tandem mass spectrometry for a neonatal-screening pilot study in Japan.

Authors:  Y Shigematsu; I Hata; Y Kikawa; M Mayumi; Y Tanaka; M Sudo; N Kado
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-08-06

4.  Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study.

Authors:  J C Feoli-Fonseca; E Lévy; M Godard; M Lambert
Journal:  J Pediatr       Date:  1998-09       Impact factor: 4.406

5.  Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific.

Authors:  R Fingerhut; W Röschinger; A C Muntau; T Dame; J Kreischer; R Arnecke; A Superti-Furga; H Troxler; B Liebl; B Olgemöller; A A Roscher
Journal:  Clin Chem       Date:  2001-10       Impact factor: 8.327

6.  Glycogen storage disease type I: diagnosis and phenotype/genotype correlation.

Authors:  Dietrich Matern; Hans Hermann Seydewitz; Deeksha Bali; Christine Lang; Yuan-Tsong Chen
Journal:  Eur J Pediatr       Date:  2002-07-27       Impact factor: 3.183

Review 7.  Disturbed lipid metabolism in glycogen storage disease type 1.

Authors:  Robert H J Bandsma; G Peter A Smit; Folkert Kuipers
Journal:  Eur J Pediatr       Date:  2002-07-13       Impact factor: 3.183

8.  Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease.

Authors:  H L Greene; L L Swift; H R Knapp
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

9.  Renal handling of carnitine in secondary carnitine deficiency disorders.

Authors:  C A Stanley; G T Berry; M J Bennett; S M Willi; W R Treem; D E Hale
Journal:  Pediatr Res       Date:  1993-07       Impact factor: 3.756

10.  Dicarboxylic aciduria during ketotic phases in various types of glycogen storage disease.

Authors:  J E Pettersen; A Winsnes
Journal:  Acta Paediatr Scand       Date:  1981
View more
  9 in total

Review 1.  Dietary dilemmas in the management of glycogen storage disease type I.

Authors:  Kaustuv Bhattacharya
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

Review 2.  Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Nat Rev Endocrinol       Date:  2010-10-26       Impact factor: 43.330

3.  Insulin-resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria?

Authors:  Alessandro Rossi; Margherita Ruoppolo; Pietro Formisano; Guglielmo Villani; Lucia Albano; Giovanna Gallo; Daniela Crisci; Augusta Moccia; Giancarlo Parenti; Pietro Strisciuglio; Daniela Melis
Journal:  J Inherit Metab Dis       Date:  2018-02-12       Impact factor: 4.982

Review 4.  Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.

Authors:  Suzanne W Boyer; Lisa J Barclay; Lindsay C Burrage
Journal:  Nutr Clin Pract       Date:  2015-06-16       Impact factor: 3.080

5.  Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.

Authors:  Patrícia Margarida Serra Carvalho; Nuno José Marques Mendes Silva; Patrícia Glória Dinis Dias; João Filipe Cordeiro Porto; Lèlita Conceição Santos; José Manuel Nascimento Costa
Journal:  J Diabetes Metab Disord       Date:  2013-06-06

6.  Natural Progression of Canine Glycogen Storage Disease Type IIIa.

Authors:  Elizabeth D Brooks; Haiqing Yi; Stephanie L Austin; Beth L Thurberg; Sarah P Young; John C Fyfe; Priya S Kishnani; Baodong Sun
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

Review 7.  Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions.

Authors:  Terry G J Derks; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2015-01-30       Impact factor: 4.982

8.  Non-ketogenic combination of nutritional strategies provides robust protection against seizures.

Authors:  Glenn Dallérac; Julien Moulard; Jean-François Benoist; Stefan Rouach; Stéphane Auvin; Angèle Guilbot; Loïc Lenoir; Nathalie Rouach
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

9.  Glycogen storage disease type 1a in the Ohio Amish.

Authors:  Ethan M Scott; Olivia K Wenger; Elizabeth Robinson; Kristina Colling; Miraides F Brown; Jennifer Hershberger; Kadakkal Radhakrishnan
Journal:  JIMD Rep       Date:  2022-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.